CDKN1A and Insulin resistance: Use of the SGLT2 inhibitor canagliflozin in HFD-induced obese C57BL/6 mice reduced VAT senescence (attenuated SA-β-gal activity and Cdkn1a expression), oxidative stress, metaflammation (numbers of CLS), T-cell anergy and inhibition of clearance of PD-L1 expressing senescent cells, and metabolic dysfunction (glucose intolerance and insulin resistance).